Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Dragonfly Therapeutics
National Cancer Institute (NCI)
RasCal Therapeutics, Inc.
National Cancer Institute (NCI)
Dragonfly Therapeutics
BeOne Medicines
AstraZeneca
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Conjupro Biotherapeutics, Inc.
Avacta Life Sciences Ltd
Janssen Research & Development, LLC
Stanford University
Boehringer Ingelheim
Seagen Inc.
Incyte Corporation
Pfizer
Boehringer Ingelheim
ArriVent BioPharma, Inc.
Seagen Inc.
University of Iowa
Johnson & Johnson Enterprise Innovation Inc.
Seagen Inc.
Ono Pharmaceutical Co. Ltd
Eli Lilly and Company
Pfizer
Novartis
Memorial Sloan Kettering Cancer Center
Fred Hutchinson Cancer Center
Exelixis
Novartis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
Tomsk National Research Medical Center of the Russian Academy of Sciences
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Barbara Ann Karmanos Cancer Institute
Kivu Bioscience Inc.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
EpiBiologics
Emory University
University Hospital Heidelberg
AstraZeneca
Alterome Therapeutics, Inc.